Equities research analysts expect Masimo Co. (NASDAQ:MASI) to report $0.68 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Masimo’s earnings. The highest EPS estimate is $0.69 and the lowest is $0.67. Masimo posted earnings of $0.70 per share during the same quarter last year, which would indicate a negative year over year growth rate of 2.9%. The firm is scheduled to issue its next earnings results on Tuesday, October 30th.
On average, analysts expect that Masimo will report full year earnings of $2.90 per share for the current year, with EPS estimates ranging from $2.90 to $2.91. For the next financial year, analysts anticipate that the business will report earnings of $3.03 per share, with EPS estimates ranging from $3.00 to $3.08. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for Masimo.
Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Wednesday, August 1st. The medical equipment provider reported $0.73 EPS for the quarter, beating the consensus estimate of $0.71 by $0.02. Masimo had a net margin of 15.30% and a return on equity of 21.49%. The business had revenue of $211.62 million during the quarter, compared to analysts’ expectations of $207.85 million. During the same period in the previous year, the business posted $0.83 EPS. The business’s quarterly revenue was up 10.0% compared to the same quarter last year.
Shares of NASDAQ MASI opened at $120.61 on Monday. Masimo has a 12 month low of $80.69 and a 12 month high of $126.89. The company has a market cap of $6.45 billion, a price-to-earnings ratio of 49.23, a price-to-earnings-growth ratio of 2.91 and a beta of 1.00.
In related news, insider Ramshorst David J. Van sold 1,325 shares of the business’s stock in a transaction on Monday, October 1st. The shares were sold at an average price of $125.00, for a total value of $165,625.00. Following the completion of the sale, the insider now owns 2,325 shares of the company’s stock, valued at approximately $290,625. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Bilal Muhsin sold 20,000 shares of the business’s stock in a transaction on Thursday, September 6th. The stock was sold at an average price of $117.75, for a total transaction of $2,355,000.00. Following the completion of the sale, the executive vice president now directly owns 10,000 shares of the company’s stock, valued at approximately $1,177,500. The disclosure for this sale can be found here. Over the last quarter, insiders sold 765,380 shares of company stock valued at $90,720,456. Company insiders own 12.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of MASI. FMR LLC increased its holdings in Masimo by 6,605.4% in the 2nd quarter. FMR LLC now owns 1,821,994 shares of the medical equipment provider’s stock worth $177,918,000 after acquiring an additional 1,794,822 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in Masimo by 102.0% in the 1st quarter. Point72 Asset Management L.P. now owns 1,381,945 shares of the medical equipment provider’s stock worth $121,542,000 after acquiring an additional 697,920 shares in the last quarter. Schroder Investment Management Group increased its holdings in Masimo by 77.2% in the 2nd quarter. Schroder Investment Management Group now owns 799,435 shares of the medical equipment provider’s stock worth $106,225,000 after acquiring an additional 348,169 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec purchased a new stake in Masimo in the 2nd quarter worth $21,483,000. Finally, Marshall Wace LLP purchased a new stake in Masimo in the 2nd quarter worth $18,072,000. 83.25% of the stock is owned by institutional investors.
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.